___

• Sahn SA, Heffner JE. Pleural fluid analysis. In: Light RW, Lee YCG, editors. Textbook of Pleural Diseases. 2nd ed. London, UK: Arnold Press; 2008. pp. 26-27.
• Marel M, Zrustova M, Stasny B, Light RW. The incidence of pleural effusion in a well-defined region: epidemiologic study in central Bohemia. Chest 1993; 104: 1486-1489.
• Hooper C, Lee YC, Maskell N; BTS Pleural Guideline Group. Investigation of a unilateral pleural effusion in adults: British Thoracic Society Pleural Disease Guideline 2010. Thorax 2010; 65: 4-17.
• Light RW. Clinical practice: pleural effusion. N Engl J Med 2002; 346: 1971-1977.
• Yilmaz Turay U, Yildirim Z, Turkoz Y, Biber C, Erdogan Y, Keyf AI, Uğurman F, Ayaz A, Ergün P, Harputluoğlu M. Use of pleural fluid C-reactive protein in diagnosis of pleural effusions. Respir Med 2000; 94: 432-435.
• Bottazzi B, Bastone A, Doni A, Garlanda C, Valentino S, Deban L, Maina V, Cotena A, Moalli F, Vago L et al. The long pentraxin PTX3 as a link among innate immunity, inflammation, and female fertility. J Leukoc Biol 2006; 79: 909-912.
• Wisniewski HG, Vilcek J. Cytokine-induced gene expression at the crossroads of innate immunity, inflammation and fertility: TSG-6 and PTX3/TSG-14. Cytokine Growth Factor Rev 2004; 15: 129-146.
• Introna M, Alles VV, Castellano M, Picardi G, De Gioia L, Bottazzai B, Peri G, Breviario F, Salmona M, De Gregorio L et al. Cloning of mouse ptx3, a new member of the pentraxin gene family expressed at extrahepatic sites. Blood 1996; 87: 1862-1872.
• Camozzi M, Zacchigna S, Rusnati M, Coltrini D, Ramirez- Correa G, Bottazzi B, Mantovani A, Giacca M, Presta M. Pentraxin 3 inhibits fibroblast growth factor 2-dependent activation of smooth muscle cells in vitro and neointima formation in vivo. Arterioscler Thromb Vasc Biol 2005; 25: 1837-1842.
• Jaillon S, Peri G, Delneste Y, Frémaux I, Doni A, Moalli F, Garlanda C, Romani L, Gascan H, Bellocchio S et al. The humoral pattern recognition receptor PTX3 is stored in neutrophil granules and localizes in extracellular traps. J Exp Med 2007; 204: 793-804.
• Ozsu S, Abul Y, Mentese A, Bektas H, Uzun A, Ozlu T, Porcel JM. Pentraxin-3: a novel biomarker for discriminating parapneumonic from other exudative effusions. Respirology 2013; 18: 657-662.
• Yeo CD, Kim JW, Cho MR, Kang JY, Kim SJ, Kim YK, Lee SH, Park CK, Kim SH, Park MS et al. Pleural fluid pentraxin-3 for the differential diagnosis of pleural effusions. Tuberc Respir Dis 2013; 75: 244-249.
• Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJ, Ponikowski P, Poole-Wilson PA, Strömberg A, van Veldhuisen DJ, Atar D, Hoes AW et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J 2010; 12: 933-989.
• Niederman MS, Mandell LA, Anzueto A, Bass JB, Broughton WA, Campbell GD, Dean N, File T, Fine MJ, Gross PA et al. American Thoracic Society. Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med 2001; 163: 1730-1754.
• Davies HE, Davies RJ, Davies CW; BTS Pleural Disease Guideline Group. Management of pleural infection in adults: British Thoracic Society Pleural Disease Guideline 2010. Thorax 2010; 65: 41-53.
• Bottazzi B, Inforzato A, Messa M, Barbagallo M, Magrini E, Garlanda C, Mantovani A. The pentraxins PTX3 and SAP in innate immunity, regulation of inflammation and tissue remodelling. J Hepatol 2016; 64: 1416-1427.
• Schwingel FL, Pizzichini E, Kleveston T, Morato EF, Pinheiro JT, Steidle LJ, Dal-Pizzol F, Rocha CC, Pizzichini MM. Pentraxin 3 sputum levels differ in patients with chronic obstructive pulmonary disease vs asthma. Ann Allergy Asthma Immunol 2015; 115: 485-489.
• Kurt OK, Tosun M, Kurt EB, Talay F. Pentraxin 3 as a novel biomarker of inflammation in chronic obstructive pulmonary disease. Inflammation 2015; 38: 89-93.
• Garlanda C, Bottazzi B, Bastone A, Mantovani A. Pentraxins at the crossroads between innate immunity, inflammation, matrix deposition, and female fertility. Annu Rev Immunol 2005; 23: 337-366.
• Napoleone E, di Santo A, Bastone A, Peri G, Mantovani A, de Gaetano G, Donati MB, Lorenzet R. Long pentraxin PTX3 upregulates tissue factor expression in human endothelial cells: a novel link between vascular inflammation and clotting activation. Arterioscler Thromb Vasc Biol 2002; 22: 782-787.
• He X, Han B, Bai X, Zhang Y, Cypel M, Mura M, Cypel M, Mura M, Keshavjee S, Liu M. PTX3 as a potential biomarker of acute lung injury: supporting evidence from animal experimentation. Intensive Care Med 2010; 36: 356-364.
• Garlanda C, Hirsch E, Bozza S, Salustri A, De Acetis M, Nota R, Maccagno A, Riva F, Bottazzi B, Peri G et al. Non-redundant role of the long pentraxin PTX3 in anti-fungal innate immune response. Nature 2002; 420: 182-186.
• Mauri T, Coppadoro A, Bellani G, Bombino M, Patroniti N, Peri G, Mantovani A, Pesenti A. Pentraxin 3 in acute respiratory distress syndrome: an early marker of severity. Crit Care Med 2008; 36: 2302-2308.
• Mantovani A, Pesenti A. Alveolar pentraxin 3 as an early marker of microbiologically confirmed pneumonia: a threshold-finding prospective observational study. Crit Care 2014; 18: 562.
• Kiropoulos TS, Kostikas K, Oikonomidi S, Tsilioni I, Nikoulis D, Germenis A, Gourgoulianis KI. Acute phase markers for the differentiation of infectious and malignant pleural effusions. Respir Med 2007; 101: 910-918.
• Arao K, Fujiwara T, Taniguchi Y, Jinnouchi H, Sasai H, Matsumoto M, Funayama H, Ako J, Momomura S. Implications of pentraxin 3 levels in patients with acute aortic dissection. Heart Vessels 2015; 30: 211-217.